DiaMedica Therapeutics Inc (DMAC)

Etorro trading 970x250
DiaMedica Therapeutics Inc (DMAC) Logo

About DiaMedica Therapeutics Inc

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. Address: Two Carlson Parkway, Minneapolis, MN, United States, 55447

DiaMedica Therapeutics Inc News and around…

Latest news about DiaMedica Therapeutics Inc (DMAC) common stock and company :

DiaMedica Therapeutics Announces Late Breaking Data from REDUX Phase 2 Trial to be Presented at ASN Kidney Week 2021
18 Oct, 2021 FinancialContent

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that late-breaking data from the Company’s Phase 2 REDUX trial of DM199 in chronic kidney disease (CKD) will be presented at the American Society of Nephrology’s (ASN) annual Kidney Week meeting. The abstract will include an update to the Phase 2 REDUX interim data the Company announced in June 2021.

Top Buys by Top Brass: Senior VP, Clinical Operations Alcorn Jr.'s $121K Bet on DMAC
11 Oct, 2021 FinancialContent

A company's own top management tend to have the best inside view into the business, so when company officers make major buys, investors are wise to take notice. Presumably the only reason an insider would take their hard-earned cash and use it to buy stock of their company in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both..

Quite a few insiders invested in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) last year which is positive news for shareholders
08 Oct, 2021 Yahoo! Finance

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

Hedge Funds Aren’t Crazy About DiaMedica Therapeutics Inc. (DMAC) Anymore
04 Oct, 2021 Yahoo! Finance

Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that’s why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]

DiaMedica Therapeutics Announces Fast Track Designation Granted to DM199 for the Treatment of Acute Ischemic Stroke
30 Sep, 2021 FinancialContent

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track Designation to the Company’s lead candidate DM199 for the treatment of acute ischemic stroke (AIS) where tissue plasminogen activator and/or mechanical thrombectomy are not indicated or medically appropriate.

Peek Under The Hood: ITOT Has 13% Upside
29 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Core S&P Total US.

DiaMedica Therapeutics Announces Closing of $30 Million Private Placement
28 Sep, 2021 FinancialContent

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced the closing of its previously announced $30 million private placement to ten accredited investors. The Company sold approximately 7.7 million common shares at purchase price of $3.92 per share equal to the per share closing price of the Company’s common shares on September 24, 2021. After deducting estimated offering expenses, the Company received net proceeds of approximately $29.8 million.

50 Biggest Movers From Yesterday
28 Sep, 2021 FinancialContent

Gainers Red Cat Holdings, Inc. (NASDAQ: RCAT) shares surged 50% to close at $3.60 on Monday after the company said its subsidiary, ...

Mid-Day Market Update: Crude Oil Rises 2%; ASLAN Pharmaceuticals Shares Slide
27 Sep, 2021 FinancialContent

Midway through trading Monday, the Dow traded up 0.70% to 35,041.74 while the NASDAQ fell 0.51% to 14,970.85. The S&P also rose, ...

31 Stocks Moving In Monday's Mid-Day Session
27 Sep, 2021 FinancialContent

Gainers Red Cat Holdings, Inc. (NASDAQ: RCAT) shares jumped 54.1% to $3.6998 after the company said its subsidiary, Skypersonic, ...

DiaMedica Therapeutics Announces $30 Million Private Placement
27 Sep, 2021 FinancialContent

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced it has entered into a definitive agreement with ten accredited investors in a private placement of $30 million of DiaMedica’s common shares at a purchase price of $3.92 per share, equal to the per share closing price of the Company’s common shares on September 24, 2021.

DiaMedica (DMAC) Initiates Pivotal Ischemic Stroke Study
14 Sep, 2021 Yahoo! Finance

DiaMedica (DMAC) is developing its recombinant KLK1 protein candidate, DM199 for treating patients who suffered an acute ischemic stroke in the last 24 hours as well as for reducing the risk of recurrent stroke.

DiaMedica Therapeutics Initiates Pivotal Trial of DM199 for the Treatment of Acute Ischemic Stroke
13 Sep, 2021 FinancialContent

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced the initiation of the first site for its pivotal ReMEDy2 Trial, a Phase 2/3 clinical study of DM199 for the treatment of acute ischemic stroke (AIS).

DiaMedica Therapeutics to Participate at Upcoming Investor Conferences
07 Sep, 2021 FinancialContent

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the company will participate in three upcoming investor conferences. Details of the company’s participation are as follows:

We Did The Math IWC Can Go To $201
25 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Micro-Cap ETF (IWC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $200.98 per unit.

12 Penny Stocks To Buy In August 2021 According To Insiders
19 Aug, 2021 FinancialContent
4 Penny Stocks Insiders Are Buying
18 Aug, 2021 FinancialContent

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and ...

Bargain Hunters Take Note: Insider Cluster-Buying At DMAC
18 Aug, 2021 FinancialContent

A particularly strong insider buying signal is what we call a "cluster-buy" where three or more different insiders make open market purchases within a short period of one another. At DiaMedica Therapeutics Inc (DMAC), 3 different insiders purchased 75,671 shares at an average price of $3.13/share, for a total of $237,109, with the most recent purchase on August 16, 2021.

The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
13 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2021 Financial Results
11 Aug, 2021 FinancialContent

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and financial results for the quarter ended June 30, 2021. DiaMedica will host a conference call Thursday, August 12, 2021, at 7:00AM Central Time/8:00AM Eastern Time to discuss its business update and second quarter financial results.

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2021 Financial Results
11 Aug, 2021 Yahoo! Finance

MINNEAPOLIS, August 11, 2021--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and financial results for the quarter ended June 30, 2021. DiaMedica will host a conference call Thursday, August 12, 2021, at 7:00AM Central Time/8:00AM Eastern Time to discuss its business update and second quarter financial results.

The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
11 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
08 Aug, 2021 FinancialContent

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader ...

DiaMedica Therapeutics to Report Second Quarter 2021 Financial Results and Provide a Business Update August 12, 2021
05 Aug, 2021 FinancialContent

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its second quarter 2021 financial results will be released after the markets close on Wednesday, August 11th. DiaMedica will host a live conference call on Thursday, August 12th at 7:00 AM Central Time to discuss its business update and financial results.

DiaMedica Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
28 Jul, 2021 FinancialContent

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Rick Pauls, President and Chief Executive Officer, will be available for one-on-one meetings and will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 9, 2021 at 10:00 am ET. Mr. Pauls looks forward to meeting investors to discuss DiaMedica’s clinical development programs and business strategy.

DiaMedica Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
28 Jul, 2021 Yahoo! Finance

MINNEAPOLIS, July 28, 2021--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Rick Pauls, President and Chief Executive Officer, will be available for one-on-one meetings and will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 9, 2021 at 10:00 am ET. Mr. Pauls looks forward to meeting investors to discu

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
28 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
27 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Peek Under The Hood: ITOT Has 11% Upside
20 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Core S&P Total US.

The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
16 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

DiaMedica Therapeutics Inc (DMAC) is a NASDAQ Common Stock listed in , ,

970x250